T3D
0.05
233.3%
PEN
0.33
-46.8%
GML
0.045
60.7%
RGL
0.003
-40%
ENT
0.008
60%
KLR
0.54
-34.1%
AIV
0.02
53.8%
JAV
0.002
-33.3%
QXR
0.006
50%
M2R
0.002
-33.3%
AQI
0.038
35.7%
RDS
0.004
-33.3%
NPM
0.018
28.6%
AOA
0.003
-25%
AHK
0.455
28.2%
BLZ
0.003
-25%
VML
0.165
26.9%
MEM
0.003
-25%
FIN
0.005
25%
LEG
0.007
-22.2%
VRC
0.005
25%
ADG
0.004
-20%
BCM
0.023
21.1%
CAV
0.004
-20%
FL1
0.12
20%
CVB
0.14
-20%
WHK
0.012
20%
FBR
0.004
-20%
S66
0.195
18.2%
IMI
0.008
-20%
KLS
4.76
18.1%
TRM
0.042
-19.2%
PAT
0.04
17.6%
GBE
0.06
-16.7%
NXL
2.41
17%
XGL
0.02
-16.7%
AJX
0.007
16.7%
ATV
0.016
-15.8%
AVE
0.007
16.7%
LU7
0.011
-15.4%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

What’s Hot – AHN, TRP, ATX, QHL & PR1

What’s Hot, Not & Doing
Brought to you by TSN Contributor & Wealth Advisor Nick Kelso

What’s Hot – AHN, TRP, ATX, QHL & PR1
What’s Not – AGY & VHM

What’s Hot
AHN – Athena Resources Limited today closed up 100% to finish at 0.4c on $190k stock traded. The reason they were up today was because they announced the appointments of Mr John Welborn as non-executive Chairman and Mr Garry Plowright as non-executive director.

The appointments follow the approval by shareholders to issue a $1m convertible note to Fenix Resources which will exceed 30% of Athena’s shares on issue.

Athena is investigating the opportunity to leverage Fenix’s capabilities and experience to advance the Byro Magnetite Project.

TRP – Tissue Repair Limited today closed up 95% to finish at 43c on $1.9m stock traded. The reason they were up today was because they announced TGA Approval was granted for TR Pro+.

TR Pro+ is its first advanced wound healing gel product containing the proprietary active ingredient, Glucoprime (0.1%), derived from yeast.

Despite the products current regulatory status as a cosmetic, TR Pro+ sales in June reached a new high with Q3 revenue showing 130% growth over the prior quarter and expanding to over 160 clinics.

ATX – Amplia Therapeutics Limited today closed up 61% to finish at 10c on $400k stock traded. The reason they were up today was because they announced results from a phase 2b clinical trial investigating narmafotinib in the treatment of advanced pancreatic cancer.

Narmafotinib (AMP945) is the company’s best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic and other cancers, and a drug target gaining increasing attention for its role in solid tumours.

Of the 6 patients currently assessed at the four-month time point, in addition to the three confirmed partial responses, two additional patients have recorded sustained stable disease.

QHL – Quickstep Holdings Limited today closed up another 12% to finish at 38c on $220k stock traded. There was no news out today but on Tuesday they released a July business update which highlighted the successful completion of restructuring activities.

The restructure has delivered a reduction in direct production headcount of approximately 20% and a reduction in operational support headcount of a similar amount.

QHL will release its audited FY24 results in August but can confirm that the unaudited Group revenue at $99m exceeds the guidance provided in April of $94m-$96m.

PR1 – Pure Resources Limited today closed up 10% to finish at 9.5c on $830k stock traded. The reason they were up today was because they announced the acquisition of the Reedy Creek Garnet Project located in WA.

Reedy Creek is a hard-rock, high-grade, outcropping industrial garnet deposit which is situated on a live mining licence and is close to established infrastructure.

Historical high-grade drill results from Reedy Creek include 6m @ 78% garnet from surface & 10m @ 65% garnet from 2m.

What’s Not
AGY – Argosy Minerals Limited today closed down another 31% to finish at 3.4c on $2.9m stock traded. There was no news out today but yesterday they announced an update for its Rincon Lithium Project located in Argentina.

AGY has decided to suspend operations at the 2,000tpa facility and effect the necessary workforce restructuring to adjust to next phase Project requirements.

This is after acknowledging current lithium market conditions and near-term lithium price forecasts, and fiscal prudence to maintain capital preservation practices.

Rats Rant – IMPORTANT INFORMATION
The idea of this report is to be informative and hopefully point out some stocks that you wouldn’t ordinarily have seen during the day, maybe even have a laugh too.This report IS NOT personal advice. Sanlam Private Wealth Pty Ltd DOES NOT PROVIDE personal advice, Sanlam Private Wealth provides General Financial Product Advice.All advice included in The Rat’s Rant is General Advice. Please refer to the General Advice Warning. The views expressed in this report are my views and may not necessarily reflect the same views as Sanlam Private Wealth.It is very important to refer to the ASX website for information on any companies / stock that are contained in this report and as always please consult your financial adviser before acting.

Important Notice
Rat Consulting Pty Ltd (ABN 81 148 181 588 ) Authorised Representative (No 001281456) of Sanlam Private Wealth Ltd (ABN 18 136 960 775) holder of Australian Financial Services Licence (AFSL 337 927).